Enliven Therapeutics, Inc. (ELVN)

NASDAQ: ELVN · IEX Real-Time Price · USD

22.57

+0.03 (0.13%)

At close: May 31, 2024, 4:00 PM

21.57

-1.00 (-4.43%)

After-hours: May 31, 2024, 7:11 PM EDT

Enliven Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	18.96	7.77	13	9.54	5.11	Upgrade
Research & Development	64.57	31.02	38.44	32.15	19.01	Upgrade
Operating Expenses	83.53	38.79	51.44	41.7	24.12	Upgrade
Operating Income	-83.53	-38.79	-51.44	-41.7	-24.12	Upgrade
Other Expense / Income	-11.95	-1.13	-0.06	-0.34	-0.65	Upgrade
Pretax Income	-71.58	-37.66	-51.38	-41.36	-23.46	Upgrade
Net Income	-71.58	-37.66	-51.38	-41.36	-23.46	Upgrade
Preferred Dividends	0	0	0	7.86	0	Upgrade
Net Income Common	-71.58	-37.66	-51.38	-49.22	-23.46	Upgrade
Shares Outstanding (Basic)	36	3	5	3	0	Upgrade
Shares Outstanding (Diluted)	36	3	5	3	0	Upgrade
Shares Change	1037.74%	-42.31%	55.56%	1882.29%	-	Upgrade
EPS (Basic)	-2.01	-12.05	-9.48	-14.12	-133.60	Upgrade
EPS (Diluted)	-2.01	-12.05	-9.48	-14.12	-133.60	Upgrade
Free Cash Flow	-61.42	-32.69	-46.78	-37.42	-22.02	Upgrade
Free Cash Flow Per Share	-1.73	-10.46	-8.64	-10.75	-125.37	Upgrade
EBITDA	-70.98	-37.45	-51.29	-41.26	-23.43	Upgrade
Depreciation & Amortization	0.6	0.22	0.1	0.1	0.03	Upgrade
EBIT	-71.58	-37.66	-51.38	-41.36	-23.46	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).